BioSpace News Archive

Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and reported financial results for the first quarter ended March 31, 2023.

Avantik, a provider of services and products supporting diagnostic laboratories with their operations, announced that it has expanded its leadership team.

The Insight Partners published latest research report on “Male Infertility Market Size Report, Share, Trends, Growth & Key Companies Forecast to 2027 - COVID-19 Impact and Global Analysis by Test; Treatment Type; Distribution Channel

SpringWorks Therapeutics, Inc. announced today that data from two collaborator-sponsored clinical studies evaluating nirogacestat, an investigational oral gamma secretase inhibitor, in combination with B-cell maturation agent (BCMA) therapies in patients with relapsed or refractory multiple myeloma (RRMM) will be presented at the European Hematology Association (EHA) 2023 Congress, taking place in Frankfurt, Germany from June 8-11, 2023.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced its unaudited financial results for the quarter ended March 31, 2023.

Vincerx Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant Lymphoma (ICML), underscoring the company’s momentum towards delivering treatment options with the hope to transform clinical outcomes for patients.

Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced financial results for the first quarter of 2023 and recent corporate updates.

Keros Therapeutics, Inc. announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 28th Annual Congress of the European Hematology Association, to be held both virtually and in person from June 8 through 15, 2023.

ALX Oncology Holdings Inc. reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights.